Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors

被引：0
|
作者：
Rasco, Drew W.
McKean, Meredith
Haydon, Andrew Mark
Weickhardt, Andrew James
Frentzas, Sophia
Ahern, Elizabeth Stephanie
Powderly, John D., II
Wyant, Timothy
Tang, Jenny
Richards, Lori
Knickerbocker, Aron
Amit, Inbar
Ofran, Yanay
Vasselli, James Robert
机构：
[1] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] The Alfred, Melbourne, Vic, Australia
[4] Austin Hlth, Austin, Australia
[5] Monash Hlth, Melbourne, Vic, Australia
[6] Monash Univ, Melbourne, Vic, Australia
[7] Monash Med Ctr, Southern Hlth, Clayton, Qld, Australia
[8] Carolina BioOncol Inst, Huntersville, NC USA
[9] Biolojic Inc, Cambridge, MA USA
[10] Aulos Biosci Inc, Larkspur, CA USA
[11] Bioloj Design, Rehovot, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2527
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: Interim results
    Frentzas, Sophia
    Ahern, Elizabeth Stephanie
    Weickhardt, Andrew James
    Haydon, Andrew Mark
    de Souza, Paul L.
    Powderly, John D.
    Wyant, Timothy
    Tang, Jenny
    Richards, Lori
    Knickerbocker, Aron
    Amit, Inbar
    Ofran, Yanay
    Vasselli, James Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] INITIAL RESULTS FROM DOSE ESCALATION OF A PHASE 1/2 FIRST-IN-HUMAN, OPEN LABEL STUDY OF AU-007, A MONOCLONAL ANTIBODY THAT BINDS TO IL-2 AND PREVENTS ITS BINDING TO CD25, IN PATIENTS WITH SOLID TUMORS
    Vasselli, James
    de Souza, Paul
    Frentzas, Sophia
    Weickhardt, Andrew
    Wyant, Timothy
    Tang, Jenny
    Richards, Lori
    Knickerbocker, Aron
    Amit, Inbar
    Ofran, Yanay
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A806 - A806
  • [3] Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL2Ra binding, in patients with advanced solid tumors
    Vasselli, James Robert
    Frentzas, Sophia
    Weickhardt, Andrew James
    de Souza, Paul L.
    Tang, Jenny
    Wyant, Tim
    Amit, Inbar
    Ofran, Yanay
    Knickerbocker, Aron
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Determination of the phase 2 dose of AU-007, an AI-designed human monoclonal antibody that redirects IL-2 to T-effector cells
    Wyant, T.
    McKean, M.
    Rasco, D.
    Haydon, A. M.
    Powderly, J. D.
    Weickhardt, A. J.
    Ahern, E. S.
    De Souza, P.
    Ganju, V.
    Hu-Lieskovan, S.
    Kichenadasse, G.
    Tang, J.
    Richards, L.
    Knickerbocker, A.
    Amit, I.
    Ofran, Y.
    Vasselli, J.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S172 - S172
  • [5] Disposition of basiliximab, an IL-2 receptor (CD25) chimeric monoclonal antibody, in pediatric liver transplant patients
    Kovarik, JM
    Melter, M
    Dunn, S
    Tzakis, A
    Gridelli, B
    Alonso, E
    Martin, S
    Merion, R
    Sharp, H
    Gerbeau, C
    Brambilla, R
    Hall, M
    TRANSPLANTATION, 1999, 67 (07) : S124 - S124
  • [6] A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
    Moreno, Victor
    Perets, Ruth
    Peretz-Yablonski, Tamar
    Fourneau, Nele
    Girgis, Suzette
    Guo, Yue
    Hellemans, Peter
    Verona, Raluca
    Pendas, Natalia
    Xia, Qi
    Geva, Ravit
    Calvo, Emiliano
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (01) : 93 - 104
  • [7] A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
    Victor Moreno
    Ruth Perets
    Tamar Peretz-Yablonski
    Nele Fourneau
    Suzette Girgis
    Yue Guo
    Peter Hellemans
    Raluca Verona
    Natalia Pendás
    Qi Xia
    Ravit Geva
    Emiliano Calvo
    Investigational New Drugs, 2023, 41 : 93 - 104
  • [8] Phase 1/2 study of XTX202, a tumor-activated IL-2βγ, in advanced solid tumors
    Chahoud, Jad
    Zakharia, Yousef
    McKean, Meredith
    Goel, Sanjay
    Chmielowski, Bartosz
    Hanna, Diana L.
    Daniels, Gregory A.
    Wu, Richard Cheng Han
    Rapisuwon, Suthee
    Hurley, Randolph
    Gupta, Anurag
    Duncan, Meghan
    Siu, Aigerim
    Patel, Ekta
    Fantini, Damiano
    Crowe, David
    Paramasivan, Sattanathan
    Luptakova, Katarina
    Kaufman, Howard L.
    Davar, Diwakar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] BLOCKING OF INTERLEUKIN-2 (IL-2) BINDING TO THE IL-2 RECEPTOR IS NOT REQUIRED FOR THE INVIVO ACTION OF ANTI-IL-2 RECEPTOR MONOCLONAL-ANTIBODY (MAB) .1. THE PRODUCTION, CHARACTERIZATION AND INVIVO PROPERTIES OF A NEW MOUSE ANTI-RAT IL-2 RECEPTOR MAB THAT REACTS WITH AN EPITOPE DIFFERENT TO THE ONE THAT BINDS TO IL-2 AND THE MAB ART-18O
    MOUZAKI, A
    VOLK, HD
    OSAWA, H
    DIAMANTSTEIN, T
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1987, 17 (03) : 335 - 341
  • [10] SELECTIVE TREG DEPLETION IN SOLID TUMORS WITH ALD2510, A NOVEL HUMANIZED CD25-SPECIFIC, IL-2 SPARING MONOCLONAL ANTIBODY
    Houacine, Jemila
    Marie-Cardine, Anne
    Le Roy, Aude
    Giustiniani, Jerome
    Abes, Riad
    Chretien, Anne-Sophie
    Fattori, Stephane
    Gorvel, Laurent
    Bensussan, Armand
    Olive, Daniel
    Foussat, Arnaud
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A898 - A898
12345